Drug updated on 4/18/2024

Dosage FormCream (topical; 0.005%)
Drug ClassRetinoids
Ongoing and
Completed Studies


  • Indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Latest News

loading GIF

This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Trifarotene (Aklief) is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older, targeting both facial and truncal acne.
  • Two studies were analyzed to gather information on trifarotene's efficacy and safety profile.
  • The studies highlight trifarotene's effectiveness in treating moderate acne on the face and trunk, particularly among adolescents aged 12 to 17. Success rates for treating facial acne are reported at 65.1%, and truncal acne at 66.9%.
  • Both studies confirm trifarotene's good safety profile, noting side effects such as pruritus, irritation, and sunburn, which are in line with common adverse effects associated with retinoid use but are considered manageable.
  • Although direct comparisons between trifarotene and other retinoids are not provided in the studies, they suggest that future research should include such comparisons, highlighting the convenience of its once-daily application and its effectiveness in treating both facial and truncal acne, even though cost may be a prohibitive factor.
  • Subgroup analysis indicates that trifarotene could be particularly beneficial for adolescents aged 12 to 17, who are significantly affected by acne vulgaris and require comprehensive yet tolerable treatment options.

Product Monograph / Prescribing Information

Document TitleYearSource
Aklief (trifarotene) Prescribing Information.2019Galderma Laboratories, L.P., Fort Worth, TX

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Guidelines of care for the management of acne vulgaris.2024Journal of the American Academy of Dermatology